Effect of preoperative short - Course famotidine on TILs and survival in breast cancer

Indian Journal of Cancer

Volumn 42, Issue 4, 2005, Pages 185-190

  Parshad, R ^a   Hazrah, P ^a   Kumar, S ^b   Datta Gupta, S ^a   Ray, R ^a   Bal, S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b ANNAMALAI UNIVERSITY   (India)

Author keywords

Breast cancer; Famotidine; Survival; Tumor infiltrating lymphocytes

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; ARTICLE; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MASTECTOMY; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; BIOPSY, NEEDLE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644857663     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Armitage JO, Sidner RD. Antitumour effect of cimetidine. Lancet 1979;1:882-3.
2. Thornes RD, Lynch G, Sheehan MV. Cimetidine and coumarin therapy of melanoma. Lancet 1982;2:328.
3. Khan MM, Keaney KM, Melmon KL, Clayberger C, Krensky AM. Histamine regulates the generation of human cytolytic T lymphocytes. Cell Immunol 1989;121:60-73.
4. Uotila P. Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy. Cancer Immunol Immunother 1993;37:251-4.
5. Plaut M, Lichtenstein LM, Gillespie E, Henney CS. Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol 1973;111:389-94.
6. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer. Lancet. 1994;344:1768-9.
7. Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with antihuman T-and B-cell sera. Cancer 1982;49:1456-64.
8. Usui T, Shimokawara I, Hirata K, Ebata T, Asaishi K, Hayasaka H, et al. Relationship between T cell infiltration in breast cancer tissues and prognosis Can No Rinsho 1983;29:1634-7.
9. Adams WJ, Morris DL. Pilot study - cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer. 1997;80:15-21.
10. Kelly MD, King J, Cherian M, Dwerryhouse SJ, Finlay IG, Adams WJ, et al. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Cancer. 1999;85:1658-63.
11. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet 1995;346:115.
12. Tonnesen H, Knigge U, Bulow S, Damm P, Fischerman K, Hesselfeldt P, et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988;2:990-2.
13. Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H, Danish RANX05 Colorectal Cancer Study Group. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg 2002;89:1416-22.
14. Smith T, Clark JW, Popp MB. Regression of melanoma nodules in a patient treated with ranitidine. Arch Intern Med 1987;147:1815-6.
15. Tsunoda T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tamai M, et al. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmacol 1992;14:75-81.
16. Kapoor S, Paul S, Kanti Chattopadhyay T. Effect of preoperative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: A double blind, placebo controlled, prospective randomized study J Surg Res. 2005; [Epub ahead of print].
17. Parshad R, Kapoor S, Gupta SD, Kumar A, Chattopadhyaya TK. Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol 2002;41:362-5.
18. Watanabe H, Enjoji M, Imai T. Gastric carcinoma with lymphoid stroma. Cancer. 1976;38:232-43
19. Nathanson. Spontaneous regression of malignant melanoma. A review of incidence, clinical feature and possible mechaisms. Conference on spontaneous regression of cancer. Natl Cancer Institute Monogram 1976;44:67-76.
20. Rosen PP. Medullary Carcinoma. In: Rosen PP, editors. Breast Pathology. Philadelphia: Lippincott and Raven; 1997. pp. 355-75.
21. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanism of T cell mediated cytotoxicity. Science 1994;265:528-30.
22. Hishii M, Kurnick JT, Ramirez-Montagut T, Pandolfi F. Studies of the mechanisms of cytolysis by tumor infiltrating lymphocytes. Clin Exp Immunol 1999;116:388-94.
23. Trentin L, Zambello R, Bulian P, Cerutti A, Milani A, Pirone E, et al. Functional role of IL2 receptors on tumor infiltrating lymphocytes. Br J Cancer 1994;69:1046-51.
24. Reynolds JL, Akhter JA, Magarey CJ, Schwartz P, Adams WJ, Morris DL. Histamine in human breast cancer. Br Surg 1998;85:538-41.
25. Berman JS, McFadden RG, Cruikshank WW, Center DM, Beer DJ. Functional characteristics of histamine receptor bearing mononuclear cells. II. Identification and characterization of two histamine induced human lymphokines that inhibit lymphocyte migration. J Immunol 1984;133:1495-504.
26. Rocklin RE. Histamine induced suppressor factor(HSF); effect on migration inhibitory factor(MIF)production and proliferation. J Immunol 1977;118:1734-8.
27. Rocklin RE, Greineder D, Littman BH, Melmon KL. Modulation of cellular immune function in vitro by histamine receptor bearing lymphocytes: mechanism of action. Cell Immunol 1978;37:162-73.
28. Nair MP, Cilik JM, Schwartz SA. Histamine induced suppressor factor inhibition of NK cells. Reversal with Interferon and interleukin-2. J Immunol 1986;136:2456-62.
29. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res 2000;60:3978-84.
30. Rajendra S, Mulcahy H, Patchett S, Kumar P. The effect of H2 antagonists on proliferation and apoptosis in human colorectal cancer cell lines. Dig Dis Sci 2004;49:1634-40.
31. Siegers CP, Andresen S, Keogh JP. Does Cimetidine improve pros-pects for cancer patients? A reappraisal of the evidence to date. Digestion 1999;60:415-21.
32. Osband ME, Hamilton D, Shen YJ, Cohen E, Shlesinger M, Lavin P, et al. Successful tumor immunotherapy with cimetidine in mice Lancet 1981;1:636-8.
33. Gifford RR, Ferguson RM, Voss BV. Cimetidine reduction of tumor formation in mice Lancet 1981;1:638-40.
34. Svendsen LB, Ross C, Knigge U, Frederiksen HJ, Graversen P, Kjaergard J, et al. Cimetidine as an adjuvant treatment in colorectal cancer. Dis Colon Rectum 1995;38:514-8.
35. Watson SA, Wilkinson LJ, Robertson JF, Hardcastle JD. Effect of histamine on the growth of human gastrointestinal tumors: reversal by cimetidine. Gut 1993;34:1091-6.
36. Langman MJ, Dunn JA, Whiting JL, Burton A, Hallissey MT, Fielding JW, et al. Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group. Br J Cancer 1999;81:1356-62.
37. Creagan ET, Veeder MH, Suman VJ, Burch PA, Maples WJ, Schaefer PL, et al. A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma. Am J Clin Oncol 1998;21:475-8.
38. Sagaster P, Micksche M, Flamm J, Ludwig H. Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 1995;6:999-1003.
39. Lemos B, Davio C, Gass H, Gonzalez P, Cricco G, Martin G, et al. Histamine receptors in human mammary glands, different benign lesions and mammary carcinoma. Inflamm Res 1995;44:68-9.
40. Gaffey MJ, Frierson HF Jr, Mills SE, Boyd JC, Zarbo RJ, Simpson JF, et al. Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance. Mod Pathol 1993;6:721-8.
41. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992;28A:859-64.
42. Bowrey PF, King J, Magarey C, Schwartz P, Marr P, Bolton E, et al. Histamine, mast cells and tumor cell proliferation in breast cancer: Does preoperative cimetidine administration have an effect? Br J Cancer 2000;82:167-70.
43. Dwerryhouse SJ, Soon Lee C, King J, Magarey C, Schwartz P, Morris DL. Cimetidine does not influence TIL in breast cancer. Int J Surg Investig 1999;1:191-4.
44. Lawson JA, Adams WJ, Morris DL. Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. Br J Cancer 1996;73:872-6.
45. Tutton PJ, Barkla DH. Comparison of the tumor inhibiting effects of three histamine H2-receptor antagonists. Anticancer Res 1983;3:7-10.
46. Marsigliante S, Biscozzo L, Marra A, Nicolardi G, Leo G, Lobreglio GB, et al. Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. Cancer 1999;139:33-41.
47. Zavagno G, Meggiolaro F, Pluchinotta A, Bozza F, Favretti F, Marconato R, et al. Influence of age and menopausal status on pathologic and biologic features of breast cancer. Breast 2000;9:320-8.
48. Zucali R, Mariani L, Marubini E, Kenda R, Lozza L, Rilke F, et al. Early breast cancer: evaluation of the prognostic role of the site of the primary tumor. J Clin Oncol 1998;16:1363-6.
49. Lohrisch C, Jackson J, Jones A, Mates D, Olivotto IA. Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer. J Clin Oncol 2000;18:2828-35.
50. Gaffney DK, Tsodikov A, Wiggins CL. Diminished survival in patients with inner versus outer quadrant breast cancers. J Clin Oncol 2003;21:467-72.